Acceleron Pharma Inc (XLRN) 38.41 $XLRN
FDA Recommendations, Study Publications, Recognitions, Agreements, and Acquisitions - Analyst Notes on MannKind, Acceleron, Steris, Retrophin, and NxStage Medical
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding MannKind Corp. (NASDAQ: MNKD), Acceleron Pharma, Inc. (NASDAQ: XLRN), Steris Corp. (NYSE: STE), Retrophin, Inc. (NASDAQ: RTRX), and NxStage Medical, Inc. (NASDAQ: NXTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Critical Alerts For Comcast, InvenSense, Pixelworks, Acceleron Pharma, and Teradyne Released By InvestorsObserver
PR Newswire - Thu Apr 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CMCSA, INVN, PXLW, XLRN, and TER.
3 Biggest Biotech Crashes in March
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 5:30PM CDT
March was pretty rough for the biotech sector, but the drop in some biotech stocks was simply breathtaking . Celldex Therapeutics , Acceleron , and Newlink Genetics all tumbled more than 25% last month -- far more than the 10% drop in the ...
Acceleron Pharma (XLRN) Jumps: Stock Up 13.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 8:39AM CDT
Acceleron Pharma, Inc. was a big mover last session, as its shares rose over 13% on the day.
Why Tesla Motors, Acceleron Pharma, and Ballard Power Systems Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Apr 02, 7:00PM CDT
Investors always keep an eye on employment-related numbers during the first week of the month, and today's news from the private sector pointed to healthy job creation that raised hopes of a spring thaw for the U.S. economy. The S&P 500 climbed...
'Fast Money' Recap: Downward Pressure
at The Street - Fri Mar 28, 4:00AM CDT
The trading panel discussed the market action, why Netflix is lower and why Intel and Microsoft are doing relatively well.
Acceleron, Celgene and Collaborators Announce Two Publications in Nature Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in Beta-thalassemia and Myelodysplastic Syndromes
Business Wire - Mon Mar 24, 6:30AM CDT
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN), announced the publication of two papers available online today and in the April issue of the journal Nature Medicine that describe how sotatercept and ACE-536 promote red blood cell formation through an erythropoietin (EPO) independent mechanism in mice. EPO stimulates the proliferation of early-stage red blood cell precursors to form new red blood cells. However, anemias associated with defects in the late-stages of red blood cell formation, known as ineffective erythropoiesis, are resistant to EPO treatment. These studies suggest that sotatercept and ACE-536 may promote and regulate the maturation of late-stage red blood cell precursors and this distinct activity supports the rationale for sotatercept and ACE-536 as potential novel therapies to correct anemia, including the EPO-resistant anemia, in diseases such as beta-thalassemia and myelodysplastic syndromes.
Earnings Release and Presentation Schedules, Nominations, and Financial Results - Analyst Notes on Five Prime Therapeutics, Acceleron, Emergent BioSolutions, CONMED, and ImmunoGen
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Five Prime Therapeutics, Inc. (NASDAQ: FPRX), Acceleron Pharma Inc. (NASDAQ: XLRN), Emergent BioSolutions Inc. (NYSE: EBS), CONMED Corporation (NASDAQ: CNMD), and ImmunoGen, Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Acceleron to Present at the 21st Annual Future Leaders in the Biotech Industry Conference
Business Wire - Thu Mar 20, 6:30AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its participation at the 21st Annual Future Leaders in the Biotech Industry Conference to be held on March 28, 2014 at the Millennium Broadway Hotel & Conference Center in New York City.
Acceleron Pharma (XLRN) Falls: Stock Drops 5.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:45AM CDT
Acceleron Pharma's shares fell nearly 6% on the day. This continues the recent downtrend for XLRN, as the stock is now down over 23% since Mar 5.
Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting
Business Wire - Mon Mar 17, 3:30PM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene Corporation, will present interim data from an ongoing phase 2a study of sotatercept in patients with end stage renal disease (ESRD) on hemodialysis at the National Kidney Foundation 2014 Spring Clinical Meeting. The meeting will take place on April 22-26, 2014 at the MGM Grand in Las Vegas, NV.
Financial Results Releases, Clinical Study Updates, Stock Summaries, and Strategic Agreements - Analyst Notes on Insmed, Medtronic, CR Bard, LabCorp, and Acceleron Pharma
PR Newswire - Fri Mar 07, 5:19AM CST
Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Medtronic, Inc. (NYSE: MDT), CR Bard Inc. (NYSE: BCR), Laboratory Corp. of America Holdings (NYSE: LH), and Acceleron Pharma, Inc. (NASDAQ: XLRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
What You Ought To Know About Celgene's Deal-Making Magic
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 05, 5:30PM CST
Celgene , the biotech giant best known for its $4 billion a year myeloma drug Revlimid, has been among the most active in making deals with young biotech companies. In January, Celgene made its latest deal, handing over $50 million to cozy up to...
Aegerion (AEGR) Falls: Stock Loses 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:42AM CST
Aegerion saw a big move last session, as the company’s shares fell by over 7% on the day
Acceleron to Present at Cowen and Company 34th Annual Health Care Conference
Business Wire - Thu Feb 27, 6:00AM CST
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its participation at the Cowen and Company 34th Annual Health Care Conference to be held on March 3-5, 2014 at the Marriott Copley Place Hotel in Boston, Mass.
Jazz Pharma Misses on Earnings, Outlook Encourages - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 9:50AM CST
Jazz Pharmaceuticals reported fourth-quarter 2013 adjusted (including stock-based compensation expense and depreciation) earnings of $1.56 per share.
Acceleron Pharma Reports Fourth Quarter and Year Ended 2013 Financial Results
Business Wire - Wed Feb 26, 6:00AM CST
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2013.
Standard Review for Merck's V503 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 5:20PM CST
MRK said that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for its investigational 9-valent human papillomavirus (HPV) vaccine, V503.
Orphan Drug Status for XOMA's Gevokizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 4:40PM CST
XOMA's gevokizumab already has orphan drug designation in the U.S. for three other indications.
Progenics to Raise Funds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 11:10AM CST
Progenics to raise funds for research and development (R&D) activities and general corporate purposes
FDA Recommendations, Study Publications, Recognitions, Agreements, and Acquisitions - Analyst Notes on MannKind, Acceleron, Steris, Retrophin, and NxStage Medical
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding MannKind Corp. (NASDAQ: MNKD), Acceleron Pharma, Inc. (NASDAQ: XLRN), Steris Corp. (NYSE: STE), Retrophin, Inc. (NASDAQ: RTRX), and NxStage Medical, Inc. (NASDAQ: NXTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Critical Alerts For Comcast, InvenSense, Pixelworks, Acceleron Pharma, and Teradyne Released By InvestorsObserver
PR Newswire - Thu Apr 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CMCSA, INVN, PXLW, XLRN, and TER.
3 Biggest Biotech Crashes in March
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 5:30PM CDT
March was pretty rough for the biotech sector, but the drop in some biotech stocks was simply breathtaking . Celldex Therapeutics , Acceleron , and Newlink Genetics all tumbled more than 25% last month -- far more than the 10% drop in the ...
Acceleron Pharma (XLRN) Jumps: Stock Up 13.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 8:39AM CDT
Acceleron Pharma, Inc. was a big mover last session, as its shares rose over 13% on the day.
Why Tesla Motors, Acceleron Pharma, and Ballard Power Systems Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Apr 02, 7:00PM CDT
Investors always keep an eye on employment-related numbers during the first week of the month, and today's news from the private sector pointed to healthy job creation that raised hopes of a spring thaw for the U.S. economy. The S&P 500 climbed...
'Fast Money' Recap: Downward Pressure
at The Street - Fri Mar 28, 4:00AM CDT
The trading panel discussed the market action, why Netflix is lower and why Intel and Microsoft are doing relatively well.
Acceleron, Celgene and Collaborators Announce Two Publications in Nature Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in Beta-thalassemia and Myelodysplastic Syndromes
Business Wire - Mon Mar 24, 6:30AM CDT
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN), announced the publication of two papers available online today and in the April issue of the journal Nature Medicine that describe how sotatercept and ACE-536 promote red blood cell formation through an erythropoietin (EPO) independent mechanism in mice. EPO stimulates the proliferation of early-stage red blood cell precursors to form new red blood cells. However, anemias associated with defects in the late-stages of red blood cell formation, known as ineffective erythropoiesis, are resistant to EPO treatment. These studies suggest that sotatercept and ACE-536 may promote and regulate the maturation of late-stage red blood cell precursors and this distinct activity supports the rationale for sotatercept and ACE-536 as potential novel therapies to correct anemia, including the EPO-resistant anemia, in diseases such as beta-thalassemia and myelodysplastic syndromes.
Earnings Release and Presentation Schedules, Nominations, and Financial Results - Analyst Notes on Five Prime Therapeutics, Acceleron, Emergent BioSolutions, CONMED, and ImmunoGen
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Five Prime Therapeutics, Inc. (NASDAQ: FPRX), Acceleron Pharma Inc. (NASDAQ: XLRN), Emergent BioSolutions Inc. (NYSE: EBS), CONMED Corporation (NASDAQ: CNMD), and ImmunoGen, Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Acceleron to Present at the 21st Annual Future Leaders in the Biotech Industry Conference
Business Wire - Thu Mar 20, 6:30AM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its participation at the 21st Annual Future Leaders in the Biotech Industry Conference to be held on March 28, 2014 at the Millennium Broadway Hotel & Conference Center in New York City.
Acceleron Pharma (XLRN) Falls: Stock Drops 5.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:45AM CDT
Acceleron Pharma's shares fell nearly 6% on the day. This continues the recent downtrend for XLRN, as the stock is now down over 23% since Mar 5.
Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting
Business Wire - Mon Mar 17, 3:30PM CDT
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene Corporation, will present interim data from an ongoing phase 2a study of sotatercept in patients with end stage renal disease (ESRD) on hemodialysis at the National Kidney Foundation 2014 Spring Clinical Meeting. The meeting will take place on April 22-26, 2014 at the MGM Grand in Las Vegas, NV.
Financial Results Releases, Clinical Study Updates, Stock Summaries, and Strategic Agreements - Analyst Notes on Insmed, Medtronic, CR Bard, LabCorp, and Acceleron Pharma
PR Newswire - Fri Mar 07, 5:19AM CST
Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Medtronic, Inc. (NYSE: MDT), CR Bard Inc. (NYSE: BCR), Laboratory Corp. of America Holdings (NYSE: LH), and Acceleron Pharma, Inc. (NASDAQ: XLRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
What You Ought To Know About Celgene's Deal-Making Magic
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 05, 5:30PM CST
Celgene , the biotech giant best known for its $4 billion a year myeloma drug Revlimid, has been among the most active in making deals with young biotech companies. In January, Celgene made its latest deal, handing over $50 million to cozy up to...
Aegerion (AEGR) Falls: Stock Loses 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:42AM CST
Aegerion saw a big move last session, as the company’s shares fell by over 7% on the day
Acceleron to Present at Cowen and Company 34th Annual Health Care Conference
Business Wire - Thu Feb 27, 6:00AM CST
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its participation at the Cowen and Company 34th Annual Health Care Conference to be held on March 3-5, 2014 at the Marriott Copley Place Hotel in Boston, Mass.
Jazz Pharma Misses on Earnings, Outlook Encourages - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 9:50AM CST
Jazz Pharmaceuticals reported fourth-quarter 2013 adjusted (including stock-based compensation expense and depreciation) earnings of $1.56 per share.
Acceleron Pharma Reports Fourth Quarter and Year Ended 2013 Financial Results
Business Wire - Wed Feb 26, 6:00AM CST
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2013.
Standard Review for Merck's V503 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 5:20PM CST
MRK said that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for its investigational 9-valent human papillomavirus (HPV) vaccine, V503.
Orphan Drug Status for XOMA's Gevokizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 4:40PM CST
XOMA's gevokizumab already has orphan drug designation in the U.S. for three other indications.
Progenics to Raise Funds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 11:10AM CST
Progenics to raise funds for research and development (R&D) activities and general corporate purposes
